Stocks · News reference
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150
Wolfe Research initiates coverage on Bright Minds Biosciences (NASDAQ:DRUG) with a Outperform rating and announces Price Target of $150.
BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.